Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/novel-agents-for-the-management-of-endocrine-resistant-breast-cancer-s3HIfIZQvz
References (37)
-
C. Lefebvre, T. Bachelot, T. Filleron, Marion Pedrero, M. Campone, J. Soria, C. Massard, C. Lévy, M. Arnedos, M. Lacroix-Triki, Julie Garrabey, Y. Boursin, M. Deloger, Yu Fu, F. Commo, V. Scott, L. Lacroix, M. Dieci, M. Kamal, V. Diéras, A. Gonçalves, Jean-Marc Ferrerro, G. Romieu, L. Vanlemmens, M. Reynier, J. Thery, F. Du, S. Guiu, F. Dalenc, G. Clapisson, H. Bonnefoi, M. Jimenez, C. Tourneau, F. André (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective AnalysisPLoS Medicine, 13
-
G. Hortobagyi, S. Paluch-Shimon, K. Petráková, C. Villanueva, A. Chan, A. Nusch, Y. Yap, L. Hart, A. Favret, N. Marschner, G. Sonke, H. Ohnstad, C. Arteaga, F. Su, Wei He, M. Miller, S. Stemmer (2018)
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.Journal of Clinical Oncology, 36
-
J. Baselga, S. Im, H. Iwata, J. Cortés, M. Laurentiis, Zefei Jiang, C. Arteaga, W. Jonat, M. Clemons, Yoshinori Ito, A. Awada, S. Chia, A. Jagiełło-Gruszfeld, B. Pistilli, L. Tseng, S. Hurvitz, N. Masuda, M. Takahashi, P. Vuylsteke, S. Hachemi, Bharani Dharan, E. Tomaso, P. Urban, C. Massacesi, M. Campone (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 18 7
-
I. Mayer, V. Abramson, L. Formisano, J. Balko, M. Estrada, M. Sanders, D. Juric, D. Solit, M. Berger, H. Won, Yisheng Li, L. Cantley, E. Winer, C. Arteaga (2016)
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerClinical Cancer Research, 23
-
R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey Kulyk, J. Ettl, Ravi Patel, T. Pintér, Marcus Schmidt, Y. Shparyk, A. Thummala, N. Voytko, C. Fowst, Xin Huang, Sindy Kim, S. Randolph, D. Slamon (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.The Lancet. Oncology, 16 1
-
M. Piccart, G. Hortobagyi, M. Campone, K. Pritchard, F. Lebrun, Yoshinori Ito, S. Noguchi, Alejandra Perez, H. Rugo, I. Deleu, H. Burris, L. Provencher, P. Neven, M. Gnant, M. Shtivelband, C. Wu, Jenna Fan, W. Feng, T. Taran, J. Baselga (2014)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.Annals of oncology : official journal of the European Society for Medical Oncology, 25 12
-
G. Sledge, M. Toi, P. Neven, J. Sohn, Kenichi Inoue, X. Pivot, O. Burdaeva, M. Okera, N. Masuda, P. Kaufman, H. Koh, E. Grischke, Martin Frenzel, Yong Lin, S. Barriga, I. Smith, N. Bourayou, A. Llombart-Cussac (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 25
-
H. Rugo, J. Delord, S. Im, P. Ott, S. Piha-Paul, Philippe Bédard, J. Sachdev, C. Tourneau, E. Brummelen, A. Varga, R. Salgado, S. Loi, S. Saraf, Dina Pietrangelo, V. Karantza, A. Tan (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast CancerClinical Cancer Research, 24
-
M. Dickler, S. Tolaney, H. Rugo, J. Cortés, V. Diéras, D. Patt, H. Wildiers, C. Hudis, J. O’Shaughnessy, E. Zamora, D. Yardley, Martin Frenzel, A. Koustenis, J. Baselga (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast CancerClinical Cancer Research, 23
-
T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J. Eymard, M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. Kouri, E. Pujade-Lauraine (2012)
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 22
-
H. Weir, R. Bradbury, M. Lawson, A. Rabow, D. Buttar, R. Callis, J. Curwen, Camila Almeida, P. Ballard, Michael Hulse, Craig Donald, Lyman Feron, Galith Karoutchi, P. Macfaul, T. Moss, R. Norman, S. Pearson, Michael Tonge, G. Davies, G. Walker, Zena Wilson, R. Rowlinson, Steve Powell, C. Sadler, Graham Richmond, B. Ladd, Ermira Pazolli, A. Mazzola, C. D’Cruz, C. savi (2016)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.Cancer research, 76 11
-
C. Fribbens, B. O’Leary, L. Kilburn, S. Hrebien, I. Garcia-Murillas, M. Beaney, M. Cristofanilli, F. André, S. Loi, S. Loibl, John Jiang, C. Bartlett, M. Koehler, M. Dowsett, J. Bliss, S. Johnston, N. Turner (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
-
S. Yeruva, Fengmin Zhao, K. Miller, Amye Tevaarwerk, L. Wagner, R. Gray, J. Sparano, R. Connolly (2018)
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancerNPJ Breast Cancer, 4
-
D. Yardley, R. Ismail-Khan, B. Melichar, M. Lichinitser, P. Munster, P. Klein, S. Cruickshank, K. Miller, M. Lee, J. Trepel (2013)
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 17
-
J. Baselga, S. Dent, J. Cortés, Y. Im, V. Diéras, N. Harbeck, I. Krop, S. Verma, T. Wilson, Huan Jin, Lijia Wang, F. Schimmoller, J. Hsu, Jing He, M. Delaurentiis, P. Drullinsky, W. Jacot (2018)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.Journal of Clinical Oncology
-
J. Dixon (2014)
Endocrine Resistance in Breast CancerNew Journal of Science, 2014
-
R. Bose, Shyam Kavuri, Adam Searleman, W. Shen, D. Shen, D. Koboldt, J. Monsey, Nicholas Goel, Adam Aronson, Shunqiang Li, Cynthia Ma, L. Ding, E. Mardis, M. Ellis (2013)
Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer discovery, 3 2
-
Weiyi Toy, H. Weir, P. Razavi, M. Berger, W. Wong, E. Stanchina, Joœe Baselga, S. Chandarlapaty (2016)
Abstract 863: Differential activity and SERD sensitivity of clinical ESR1 mutationsCancer Research, 76
-
Erin Hayes, J. Lewis-Wambi (2015)
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNABreast Cancer Research : BCR, 17
-
M. Mancuso, S. Massarweh (2016)
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.Current problems in cancer, 40 2-4
-
S. Chandarlapaty, David Chen, Wei He, P. Sung, A. Samoila, Daoqi You, T. Bhatt, P. Patel, M. Voi, M. Gnant, G. Hortobagyi, J. Baselga, M. Moynahan (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.JAMA oncology, 2 10
-
L. Formisano, Yao Lu, V. Jansen, J. Bauer, A. Hanker, P. Ericsson, K. Lee, Mj Nixon, A. Guerrero-Zotano, L. Schwarz, M. Sanders, D. Sudhan, T. Dugger, Cruz, A. Behdad, M. Cristofanilli, A. Bardia, J. O’Shaughnessy, I. Mayer, C. Arteaga (2017)
Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancerCancer Research, 78
-
R. Saksena, S. Wong (2013)
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.Breast cancer, 5
-
A. Leo, S. Johnston, K. Lee, E. Ciruelos, P. Lønning, W. Janni, R. O'Regan, M. Mouret-Reynier, D. Kalev, D. Egle, T. Csőszi, R. Bordonaro, T. Decker, V. Tjan-Heijnen, S. Blau, A. Schirone, D. Weber, M. El-Hashimy, Bharani Dharan, D. Sellami, T. Bachelot (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 19 1
-
N. Kornblum, Fengmin Zhao, J. Manola, P. Klein, B. Ramaswamy, A. Brufsky, P. Stella, B. Burnette, M. Telli, D. Makower, P. Cheema, C. Truica, A. Wolff, G. Soori, B. Haley, T. Wassenaar, L. Goldstein, K. Miller, J. Sparano (2018)
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 16
-
E. Mayer, S. Wander, M. Regan, A. Demichele, A. Forero, M. Rimawi, Cynthia Ma, M. Cristofanilli, C. Anders, C. Bartlett, M. Koehler, E. Winer, H. Burstein (2018)
Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancerCancer Research, 78
-
R. Clarke, J. Tyson, J. Dixon (2015)
Endocrine resistance in breast cancer – An overview and updateMolecular and Cellular Endocrinology, 418
-
M. Salkeni, Samantha Hall (2017)
Metastatic breast cancer: Endocrine therapy landscape reshapedAvicenna Journal of Medicine, 7
-
R. Finn, Miguel Martín, H. Rugo, Stephen Jones, S. Im, K. Gelmon, N. Harbeck, O. Lipatov, J. Walshe, S. Moulder, E. Gauthier, D. Lu, S. Randolph, V. Diéras, D. Slamon (2016)
Palbociclib and Letrozole in Advanced Breast Cancer.The New England journal of medicine, 375 20
-
M. Goetz, M. Toi, M. Campone, J. Sohn, S. Paluch-Shimon, J. Huober, I. Park, O. Trédan, Shin-Cheh Chen, L. Manso, O. Freedman, Georgina Jaliffe, T. Forrester, Martin Frenzel, S. Barriga, I. Smith, N. Bourayou, A. Leo (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 32
-
D. Tripathy, S. Im, M. Colleoni, F. Franke, A. Bardia, N. Harbeck, S. Hurvitz, L. Chow, J. Sohn, K. Lee, S. Campos-Gómez, R. Vázquez, K. Jung, K. Babu, P. Wheatley-Price, M. Laurentiis, Y. Im, S. Kuemmel, N. El-Saghir, Mei-Ching Liu, G. Carlson, G. Hughes, I. Díaz-Padilla, C. Germa, S. Hirawat, Yen-Shen Lu (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.The Lancet. Oncology, 19 7
-
D. Juric, R. Ismail-Khan, M. Campone, L. García-Estévez, C. Becerra, R. Boer, E. Hamilton, I. Mayer, R. Hui, K. Lathrop, O. Pagani, S. Asano, S. Bhansali, V. Zhang, B. Hewes, P. Munster (2016)
Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysisCancer Research, 76
-
J. Ro, F. André, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. Bartlett, Ke Zhang, C. Giorgetti, S. Randolph, M. Koehler, M. Cristofanilli (2015)
PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18_suppl
-
M. Dickler, A. Bardia, I. Mayer, E. Winer, P. Rix, J. Hager, Meng Chen, Iris Chan, E. Chow-Maneval, C. Arteaga, J. Baselga (2015)
Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancerCancer Research, 75
-
J. Cortés, S. Im, E. Holgado, J. Peréz-García, P. Schmid, M. Chávez-MacGregor (2017)
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.Cancer treatment reviews, 61
-
J. Beaver, B. Park (2012)
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.Future oncology, 8 6
-
David Hyman, S. Piha-Paul, H. Won, J. Rodón, C. Saura, Geoffrey Shapiro, D. Juric, David Quinn, V. Moreno, B. Doger, Ingrid Mayer, V. Boni, E. Calvo, S. Loi, A. Lockhart, J. Erinjeri, M. Scaltriti, G. Ulaner, J. Patel, Jiabin Tang, H. Beer, S. Selcuklu, Aphrothiti Hanrahan, N. Bouvier, Myra Melcer, R. Murali, A. Schram, L. Smyth, K. Jhaveri, Bob Li, A. Drilon, James Harding, G. Iyer, Barry Taylor, Michael Berger, R. Cutler, Feng Xu, A. Butturini, L. Eli, G. Mann, C. Farrell, A. Lalani, R. Bryce, Carlos Arteaga, F. Meric-Bernstam, J. Baselga, D. Solit (2018)
HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature, 554
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-018-0298-3
- Publisher site
- See Article on Publisher Site
Abstract
Purpose of Review Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer will ulti- mately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer. Recent Findings Estrogen receptor 1 mutations (ESR1) occur in the majority of patients with HR+/HER2− metastatic breast cancer after prolonged exposure to aromatase inhibitors. Data from the SoFEA trial showed that patients had improved progression-free survival (PFS) after taking fulvestrant compared with exemestane. Fulvestrant is currently the only selective estrogen receptor degrader (SERD) available and development of oral novel SERDs with higher bioavailability and potency are currently being investigated. Summary Despite significant advances in the treatment of HR+/HER2− breast cancer over the past four decades, a significant proportion of patients do still develop endocrine resistance following optimal endocrine therapy. In this review, we aim to provide an overview of the different classes of novel agents currently being investigated to overcome endocrine resistance. . . . . . Keywords Hormone receptor positive Breast cancer Endocrine resistance Aromatase inhibitor SERD ESR1 Introduction endocrine therapy-based systemic therapies such as cytotoxic chemotherapy. Targeted therapy that can overcome or delay Hormone
Journal
Current Breast Cancer Reports – Springer Journals
Published: Nov 15, 2018